On this page
- Quick reference
- Dosage chart and four steps
- Supplies needed
- Vial and research context
- Protocol Overview
- Dosing Protocol
- Storage Instructions
- Important Notes
- How This Works
- Potential Benefits & Side Effects
- Lifestyle Factors
- Injection Technique
- Important Note
- Sources and Further Reading
- Related research, protocols, and guides
MOTS-C Quick Reference (5 mg Vial)
- Vial contents
- 5 mg MOTS-C
- Final volume
- 3 mL
- Concentration
- 1.67 mg/mL
- One U-100 unit
- 16.67 mcg in 0.01 mL
Research context: For evidence on mechanisms, human and preclinical research, limitations, and safety, read MOTS-c Peptide: Benefits, Uses, Side Effects, Dosage, and Research.
MOTS-C Dosage Chart
Dosing & Reconstitution Guide
Educational guide for reconstitution and daily dosing
Standard / Gradual Approach (3 mL = ~1.67 mg/mL)
| Week | Daily Dose (mcg) | Units (per injection) (mL) |
|---|---|---|
| Weeks 1–2 | 500 mcg (0.5 mg) | 30 units (0.30 mL) |
| Weeks 3–4 | 1000 mcg (1.0 mg) | 60 units (0.60 mL) |
| Weeks 5–6 | 1500 mcg (1.5 mg) | 90 units (0.90 mL) |
| Weeks 7–8 | 2000 mcg (2.0 mg) | 120 units (two 60‑unit injections)* |
Frequency: Inject once daily subcutaneously (morning administration preferred). *For 2.0 mg doses (120 units total), split into two separate 60‑unit injections at different sites, or use a more concentrated 2.0 mL reconstitution (2.5 mg/mL → 80 units for 2 mg). Alternate protocol: Some users employ 2–3 injections per week at higher per‑dose amounts (e.g., 3–5 mg twice weekly); consult literature for guidance[6].
Reconstitution Steps
- Draw 3.0 mL bacteriostatic water with a sterile syringe.
- Inject slowly down the vial wall; avoid foaming.
- Gently swirl/roll until dissolved (do not shake vigorously).
- Label with reconstitution date and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light. Follow documented, formulation-specific discard guidance[12].
Supplies Needed
Plan based on an 8–16 week daily protocol with gradual titration.
-
Peptide Vials (MOTS-C, 5 mg each):
- 8 weeks: approximately 12 vials required (average ~1.1 mg/day)
- 12 weeks: approximately 18 vials required
- 16 weeks: approximately 24 vials required
-
Insulin Syringes (U‑100):
- Per week: 7 syringes (1/day)
- 8 weeks: 56 syringes
- 12 weeks: 84 syringes
- 16 weeks: 112 syringes
-
Bacteriostatic Water (10 mL bottles): Use ~3.0 mL per vial for reconstitution.
- 8 weeks (12 vials): 36 mL — 4 bottles required (10 mL each)
- 12 weeks (18 vials): 54 mL — 6 bottles required (10 mL each)
- 16 weeks (24 vials): 72 mL — 8 bottles required (10 mL each)
-
Alcohol Swabs: One for the vial stopper + one for the injection site each day.
- Per week: 14 swabs (2/day)
- 8 weeks: 112 swabs — 2 boxes required (100 swabs each)
- 12 weeks: 168 swabs — 2 boxes required (100 swabs each)
- 16 weeks: 224 swabs — 3 boxes required (100 swabs each)
PeptideDosages has no affiliation with Pure Lab Peptides and receives no commission from these Pure Lab links. Supplier pages are not scientific evidence or proof of suitability for human use.
MOTS-C Vial and Research Context
- Reconstitute: Add 3.0 mL bacteriostatic water → ~1.67 mg/mL concentration.
- Typical daily range: 500–1500 mcg once daily (gradual titration from 500 mcg).
- Easy measuring: At 1.67 mg/mL, 1 unit = 0.01 mL ≈ 16.7 mcg on a U‑100 insulin syringe.
- Storage: Lyophilized: freeze at −20 °C (−4 °F); after reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F); follow documented, formulation-specific discard guidance.
MOTS-C is a 16‑amino-acid mitochondrial‑derived peptide encoded in the mtDNA 12S rRNA region[1][2]. Discovered in 2015, it enhances metabolic homeostasis through AMPK activation[1][3], increases sharply with exercise (~12‑fold in muscle)[3], and declines with age. This educational protocol presents a once‑daily subcutaneous approach aligned with preclinical findings and emerging clinical use.
Protocol Overview
Concise summary of the once‑daily regimen based on preclinical evidence.
- Goal: Support metabolic homeostasis, enhance insulin sensitivity, and promote healthy aging through AMPK activation[1][2].
- Schedule: Daily subcutaneous injections for 4–8 weeks, followed by an equal‑length break (cycling approach).
- Dose Range: 500–2000 mcg daily with gradual titration over weeks.
- Reconstitution: 3.0 mL per 5 mg vial (~1.67 mg/mL) for accurate unit measurements.
- Storage: Lyophilized frozen at −20 °C (−4 °F); reconstituted refrigerated at 2–8 °C (35.6–46.4 °F); follow documented, formulation-specific discard guidance[12].
Dosing Protocol
Suggested daily titration approach aligned with preclinical models[1][2].
- Start: 500 mcg (0.5 mg) daily for weeks 1–2; conservative baseline dose.
- Titrate: Increase to 1000 mcg (1.0 mg) daily for weeks 3–4, then 1500 mcg (1.5 mg) for weeks 5–6.
- Target: 1500–2000 mcg (1.5–2.0 mg) daily by weeks 7–8 if well‑tolerated.
- Frequency: Once per day (subcutaneous); morning administration preferred to mimic exercise‑induced release patterns.
- Cycle Length: 4–8 weeks on, followed by 4–8 weeks off; avoid continuous long‑term use without breaks.
- Timing: Consistent daily timing; rotate injection sites (abdomen, thighs, upper arms).
Storage Instructions
Proper storage preserves peptide quality and potency[12].
- Lyophilized: Store at −20 °C (−4 °F) in dry, dark conditions with desiccant; follow the exact product’s expiration date or validated stability data.
- Reconstituted: Refrigerate at 2–8 °C (35.6–46.4 °F); the discard interval depends on the exact formulation and product testing. General peptide stability estimates do not establish a shelf life for this vial[12].
- Handling: Allow vials to reach room temperature before opening to reduce condensation; avoid repeated freeze–thaw cycles.
- Protect from light and moisture; use aseptic technique when withdrawing doses.
Important Notes
Practical considerations for consistency and safety.
- Use new sterile insulin syringes for each injection; dispose in a sharps container.
- Rotate injection sites systematically (abdomen, thighs, upper arms) to reduce local irritation and lipohypertrophy risk[9].
- Inject slowly; wait a few seconds before withdrawing the needle to ensure complete delivery.
- Document daily dose, time, and site rotation to maintain consistency and monitor response.
- If doses fall below 30 units (0.30 mL), consider using 50‑unit or 30‑unit insulin syringes for improved readability.
- For 2.0 mg doses exceeding single‑syringe capacity (>100 units), split into two separate injections or use 2.0 mL reconstitution.
How This Works
MOTS-C is a mitochondrial‑derived peptide that activates AMPK‑driven metabolic pathways to enhance glucose uptake, increase fat oxidation, and reduce lipid accumulation in muscle and adipose tissue[1][2]. Preclinical studies demonstrate that daily MOTS-C administration (5 mg/kg i.p. in mice) prevents diet‑induced obesity and insulin resistance[2], while short 7‑day courses restore insulin sensitivity in aged mice to youthful levels. Unlike metformin (which acts primarily in the liver), MOTS-C directly targets skeletal muscle and fat tissues[2]. The peptide also translocates to the nucleus under metabolic stress to regulate nuclear gene expression[4]. Endogenous MOTS-C levels rise sharply with exercise (~12‑fold increase in muscle)[3] and decline with age, suggesting therapeutic potential for age‑related metabolic decline. No formal human clinical trials have been completed to date; current human use is investigational and based on preclinical findings[6].
Potential Benefits & Side Effects
Observations from preclinical and emerging investigational use.
Potential Benefits
- Enhanced insulin sensitivity and glucose metabolism in muscle and fat tissue[1][2]
- Increased fat oxidation and reduced diet‑induced obesity in animal models[2]
- Improved exercise capacity and muscle homeostasis during aging[3]
- Modest lifespan extension in rodents with intermittent dosing (15 mg/kg 3×/week)[2]
- No stimulation of IGF‑1 or adverse effects on glucose tolerance (contrast with growth hormone)
- Well‑tolerated in animal studies with no severe adverse effects at typical doses
Potential Side Effects
- Mild injection‑site reactions (temporary redness, inflammation, or bruising) reported anecdotally
- No severe adverse effects or organ toxicity observed in preclinical studies at standard doses[6]
- Long‑term human safety data not yet available; chronic continuous use beyond 8 weeks remains uncharacterized
- Theoretical risk of downregulation with prolonged daily use; cycling approach (4–8 weeks on, equal time off) recommended
Lifestyle Factors
Complementary strategies for optimal metabolic outcomes.
- Pair with a balanced, protein‑forward diet tailored to energy needs; MOTS-C enhances nutrient partitioning and fat utilization.
- Combine resistance training and aerobic activity to reinforce AMPK activation and metabolic adaptations[3].
- Prioritize 7–9 hours of quality sleep; MOTS-C may support mitochondrial function, but recovery remains essential.
- Manage stress through mindfulness or relaxation practices; chronic stress can impair metabolic benefits.
- Maintain hydration and consider timing injections around fasted periods (e.g., morning before breakfast) to mimic exercise‑induced patterns.
Injection Technique
General subcutaneous guidance from clinical best‑practice resources[7][8][9].
- Clean the vial stopper and injection site with alcohol swab; allow to air‑dry.
- Pinch a skinfold (1–2 inches) at the chosen site; insert the needle at 45–90° into subcutaneous tissue[7][8].
- Do not aspirate for subcutaneous injections[7]; inject slowly and steadily over 2–5 seconds.
- Withdraw needle at same angle; apply gentle pressure with clean cotton ball or alcohol pad (do not rub)[9].
- Rotate sites systematically (abdomen at least 2 inches from navel, outer thighs, upper arms) to avoid lipohypertrophy or scar tissue[9].
- Allow refrigerated solution to reach room temperature for 5–10 minutes before injection to reduce sting.
- Dispose of used syringe immediately into puncture‑proof sharps container; do not recap needle[9].
Important Note
This content is intended for therapeutic educational purposes only and does not constitute medical advice, diagnosis, or treatment. MOTS-C is an experimental research peptide that is not approved by the FDA or other regulatory agencies for human use. It is supplied strictly for laboratory research purposes and is not for human or veterinary consumption. Any discussion of human dosing is hypothetical and for informational purposes only. Individuals should not self‑administer MOTS-C outside of properly supervised clinical research. If considering off‑label use, consult a licensed healthcare professional and comply with all applicable regulations. Neither the authors nor the supplier assume liability for off‑label use or mishandling of MOTS-C.
Sources and Further Reading
- 1
Journal of Translational Medicine (2023)
— Wan W, et al. Mitochondria‑derived peptide MOTS‑c: effects and mechanisms related to stress, metabolism and aging - 2
Cell Metabolism (2015)
— Lee C, et al. The mitochondrial‑derived peptide MOTS‑c promotes metabolic homeostasis and reduces obesity and insulin resistance (PMID: 25738459) - 3
Nature Communications (2021)
— Reynolds JC, et al. MOTS‑c is an exercise‑induced mitochondrial‑encoded regulator of age‑dependent physical decline and muscle homeostasis (DOI: 10.1038/s41467-020-20790-0) - 4
Cell Metabolism (2018)
— Kim KH, et al. The Mitochondrial‑Encoded Peptide MOTS‑c Translocates to the Nucleus to Regulate Nuclear Gene Expression in Response to Metabolic Stress (PMID: 29983246) - 6
Alzheimer’s Drug Discovery Foundation (2021)
— Cognitive Vitality Profile: MOTS‑c (evidence review detailing preclinical findings and safety) - 7
CDC
— Vaccine Administration: Administering Vaccines (subcutaneous route guidance; angle, site, no aspiration) - 8
CDC
— Subcutaneous Injection Technique (PDF diagram and site guidance) - 9
NCBI Bookshelf
— Best Practices for Injections: asepsis, preparation, administration, and site rotation - 12
U.S. Food and Drug Administration
— MOTS-c bulk drug substance technical review: formulation-dependent stability and quality limitations - 15
Pure Lab Peptides
— MOTS‑C (5 mg) product page (high‑purity research peptide with batch documentation) - 11
Rapid Communications in Mass Spectrometry (2019)
— Knoop A, et al. Development of an MS‑based detection method for the mitochondrion‑derived peptide MOTS‑c in plasma for doping control (DOI: 10.1002/rcm.8337) - 12
PMC (Pharmacologic Review)
— Pharmacologic considerations of the subcutaneous route for biologics and peptides - 13Lee et al. (2015) : Original MOTS-C mouse experiments with exact CD-1 and C57BL/6 intraperitoneal exposures, frequencies, and durations.
- 14Reynolds et al. (2021) : Mouse physical-performance and aging experiments plus endogenous MOTS-C exercise measurements in ten healthy young men.
- 15U.S. Food and Drug Administration : Safety-risk page reporting that FDA had not identified human exposure data for native MOTS-C by any route.
- 16MOTS-C NOD Mouse Study (2025) : NOD mouse experiment using 0.5 mg/kg/day intraperitoneally from 7 to 18 weeks of age.
- 17Cell Metabolism (2015) — The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance (Lee C, Zeng J, Drew BG, et al.)
- 18Journal of Molecular Medicine (2019) — MOTS-c peptide regulates adipose homeostasis to prevent ovariectomy-induced metabolic dysfunction (Lu H, Wei M, Zhai Y, et al.)
- 19Nature Communications (2021) — MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis (Reynolds JC, Lai RW, Woodhead JST, et al.)
- 20Frontiers in Physiology (2023) — Role of MOTS-c in the regulation of bone metabolism (Yi X, Hu G, Yang Y, et al.)
- 21USADA Spirit of Sport (2023) — What is the MOTS-c peptide? – U.S. Anti-Doping Agency education article
- 22Experimental & Molecular Medicine (2025) — Mitochondrial-encoded peptide MOTS-c prevents pancreatic islet cell senescence to delay diabetes (Kong BS, Lee H, L'Yi S, et al.)
- 23MedlinePlus Medical Encyclopedia (2023) — Subcutaneous (SQ) injections – Patient instructions for proper technique
- 24International Journal of Molecular Sciences (2022) — MOTS-c, the Most Recent Mitochondrial Derived Peptide in Human Aging and Age-Related Diseases (Mohtashami Z, Singh MK, Salimiaghdam N, et al.)
Related research, protocols, and guides
Explore the available research context, protocol variants or comparisons, and practical guides. When vial-strength variants exist, they remain separate because vial strength, concentration, and syringe-unit calculations can differ. Related compounds and blends are comparisons only, not interchangeable.
Research overview
Other vial-strength protocols
Related protocols and comparisons